Trials / Completed
CompletedNCT01761123
Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum
An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of VXA-A1.1 by Delivery Directly to the Ileum Using the InteliSite Companion Capsule in Healthy Adult Males
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Vaxart · Industry
- Sex
- Male
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
the purpose of the study is to determine the safety and tolerability of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, when delivery is targeted to the ileum, using a radio controlled capsule. The secondary objective is to evaluate the immune response (cellular and humoral) of two doses of VXA-A1.1 oral vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VXA-A1.1 |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2013-01-04
- Last updated
- 2014-12-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01761123. Inclusion in this directory is not an endorsement.